NASDAQ:BCYCBicycle Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bicycle Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.30 +0.30 (+1.76 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$16.63Now: $17.30▼$17.4450-Day Range$14.79MA: $16.44▼$18.2152-Week Range$6.24Now: $17.30▼$19.79Volume17,900 shsAverage Volume91,461 shsMarket Capitalization$306.21 millionP/E RatioN/ADividend YieldN/ABeta-0.54 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.30, Bicycle Therapeutics has a potential upside of 23.1% from its current price of $17.30.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesBicycle Therapeutics has received 47 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBicycle Therapeutics has received 50 “underperform” votes. (Add your “underperform” vote.)Community SentimentBicycle Therapeutics has received 51.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bicycle Therapeutics and other stocks. Vote “Outperform” if you believe BCYC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BCYC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 33.79% of the stock of Bicycle Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($2.29) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -6.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.98 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCYC Previous Symbol CUSIPN/A CIKN/A Webwww.bicycletherapeutics.com Phone44-12-2326-1503Debt Debt-to-Equity RatioN/A Current Ratio7.62 Quick Ratio7.62Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$13.80 million Price / Sales22.19 Cash FlowN/A Price / Cash FlowN/A Book Value$5.27 per share Price / Book3.28Profitability EPS (Most Recent Fiscal Year)($2.77) Net Income$-30,610,000.00 Net Margins-414.57% Return on Equity-37.80% Return on Assets-29.42%Miscellaneous Employees61 Outstanding Shares17,700,000Market Cap$306.21 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:BCYC Rates by TradingView Receive BCYC News and Ratings via Email Sign-up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions How has Bicycle Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCYC shares have decreased by 2.3% and is now trading at $17.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Bicycle Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bicycle Therapeutics. When is Bicycle Therapeutics' next earnings date? Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Bicycle Therapeutics. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics Limited (NASDAQ:BCYC) issued its earnings results on Thursday, May, 7th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of $0.11 by $0.74. The company earned $1.13 million during the quarter, compared to analysts' expectations of $10.31 million. Bicycle Therapeutics had a negative net margin of 414.57% and a negative return on equity of 37.80%. View Bicycle Therapeutics' earnings history. What price target have analysts set for BCYC? 5 brokers have issued 12-month price objectives for Bicycle Therapeutics' shares. Their forecasts range from $14.00 to $27.00. On average, they expect Bicycle Therapeutics' stock price to reach $21.30 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price. View analysts' price targets for Bicycle Therapeutics. Has Bicycle Therapeutics been receiving favorable news coverage? News articles about BCYC stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bicycle Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Bicycle Therapeutics. Who are some of Bicycle Therapeutics' key competitors? Some companies that are related to Bicycle Therapeutics include Arcus Biosciences (RCUS), Akero Therapeutics (AKRO), Humanigen (HGEN), I-Mab (ARQT), DiaMedica Therapeutics (DMCAF), Athenex (ATNX), BioXcel Therapeutics (BTAI), Enanta Pharmaceuticals (ENTA), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Nabriva Therapeutics (NBRV), Arcturus Therapeutics (ARCT), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH) and VBI Vaccines (VBIV). View all competitors. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Beyond Meat (BYND), AbbVie (ABBV), Cronos Group (CRON), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Intra-Cellular Therapies (ITCI), NovaBay Pharmaceuticals (NBY), Occidental Petroleum (OXY), Pfizer (PFE) and Ring Energy (REI). Who are Bicycle Therapeutics' key executives? Bicycle Therapeutics' management team includes the following people: Dr. Kevin Lee M.B.A., Ph.D., CEO & Director (Age 51)Mr. Lee H. Kalowski, Pres & CFO (Age 38)Mr. Christian Heinis, Scientific FounderSir Gregory Winter, Co-Founder, Director & Member of Scientific Advisory Board (Age 68)Mr. Michael Skynner, Chief Operating Officer (Age 50) When did Bicycle Therapeutics IPO? (BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Bicycle Therapeutics' stock symbol? Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC." How do I buy shares of Bicycle Therapeutics? Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Bicycle Therapeutics' stock price today? One share of BCYC stock can currently be purchased for approximately $17.30. How big of a company is Bicycle Therapeutics? Bicycle Therapeutics has a market capitalization of $306.21 million and generates $13.80 million in revenue each year. The company earns $-30,610,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. Bicycle Therapeutics employs 61 workers across the globe. What is Bicycle Therapeutics' official website? The official website for Bicycle Therapeutics is www.bicycletherapeutics.com. How can I contact Bicycle Therapeutics? Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 44-12-2326-1503. This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
